Mark A. Goldsmith Sells 30,000 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Mark A. Goldsmith sold 30,000 shares of the company’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $50.36, for a total transaction of $1,510,800.00. Following the sale, the insider now owns 300,170 shares of the company’s stock, valued at $15,116,561.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Revolution Medicines Trading Down 0.8 %

RVMD stock opened at $50.00 on Friday. Revolution Medicines, Inc. has a 1-year low of $15.44 and a 1-year high of $51.00. The business’s 50 day moving average is $44.67 and its 200-day moving average is $41.16.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The business had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $0.81 million. During the same period in the prior year, the company earned ($0.92) EPS. Revolution Medicines’s quarterly revenue was down 73.8% on a year-over-year basis. On average, analysts forecast that Revolution Medicines, Inc. will post -3.35 earnings per share for the current year.

Hedge Funds Weigh In On Revolution Medicines

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its holdings in shares of Revolution Medicines by 40.8% during the fourth quarter. Wellington Management Group LLP now owns 14,882,086 shares of the company’s stock worth $426,818,000 after buying an additional 4,309,611 shares in the last quarter. Vanguard Group Inc. increased its holdings in Revolution Medicines by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 14,757,112 shares of the company’s stock valued at $475,622,000 after purchasing an additional 122,721 shares in the last quarter. Farallon Capital Management LLC raised its position in Revolution Medicines by 30.0% in the 2nd quarter. Farallon Capital Management LLC now owns 9,757,692 shares of the company’s stock valued at $378,696,000 after purchasing an additional 2,249,820 shares during the last quarter. Baker BROS. Advisors LP boosted its stake in Revolution Medicines by 46.6% in the first quarter. Baker BROS. Advisors LP now owns 7,549,249 shares of the company’s stock worth $243,312,000 after purchasing an additional 2,400,592 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Revolution Medicines by 3.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,814,310 shares of the company’s stock worth $155,166,000 after purchasing an additional 177,957 shares during the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on RVMD. Jefferies Financial Group initiated coverage on Revolution Medicines in a research note on Monday, July 8th. They set a “buy” rating and a $63.00 target price for the company. Wedbush restated an “outperform” rating and issued a $59.00 price objective on shares of Revolution Medicines in a research note on Thursday, August 8th. Bank of America boosted their target price on shares of Revolution Medicines from $48.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Barclays raised their price target on shares of Revolution Medicines from $54.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, September 27th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Revolution Medicines from $55.00 to $54.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Revolution Medicines currently has a consensus rating of “Buy” and an average target price of $54.00.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.